The Immortality Update: Deep Research on the Most Important Discoveries and News in Longevity Sciences from the Past 7 Days

Introduction: The Functional Frontier

This report synthesizes the most significant, corroborated findings in longevity science from the past seven days. The analysis maintains a specific focus on interventions designed to extend functional life—or healthspan—rather than merely prolonging chronological lifespan. The ultimate goal of modern geroscience is not simply to add years to life, but to add life to years, preserving physical, cognitive, and metabolic function into advanced age.

The past week has been marked by a convergence of discoveries across multiple domains of geroscience. Foundational research in model organisms has revealed novel, potentially centralized control mechanisms for aging, linking glial cell biochemistry and gut microbial metabolism to organism-wide longevity. Concurrently, preclinical studies in mammals have demonstrated promising molecular strategies for the targeted regeneration of neural and retinal tissues, shifting the paradigm from slowing decline to actively restoring function. Technologically, the emergence of a scalable human cell platform derived from centenarians promises to accelerate the study of resilience. Finally, a significant human observational study provides a mechanistic link between social well-being and the molecular hallmarks of aging.

This week's update will be analyzed through the lens of three emergent themes:

1. **The Neuro-Centric Control of Aging:** Evidence suggesting the nervous system may act as a master regulator of systemic aging.
2. **The Shift to Regenerative and Restorative Interventions:** A focus on repairing and rebuilding functional capacity in key tissues.
3. **Modeling Resilience over Damage:** The increasing importance of studying exceptional longevity to identify protective mechanisms, rather than solely focusing on pathological decline.

Key Findings: New Interventions and Discoveries

This section details the primary research findings of the week, providing a technical analysis of the interventions, their mechanisms of action, and the functional benefits observed in the respective model systems.

Cellular Master Regulators: Manipulating Glial pH to Extend Healthspan in *C. elegans*

Researchers at the University of Miami Miller School of Medicine have demonstrated that increasing the intracellular pH (alkalinization) of just two specific glial cells in the nematode *C. elegans* is sufficient to extend lifespan, enhance stress resistance, and protect against neurodegeneration-associated protein aggregation.[1] Published in *Science Advances*, this study provides compelling evidence for a centralized, non-neuronal control mechanism for organism-wide aging.[1]

The intervention involved the genetic knockout of the chloride channel CLH-1 in a pair of glial cells known as AMsh glia. The loss of this channel's function led to an increase in intracellular alkalinity. This highly localized pH shift triggered a systemic, organism-wide response, including the upregulation of protective gene programs related to antioxidant defense and autophagy (cellular recycling).[1] This finding is significant because it suggests that the aging process is not merely a collection of independent, cell-autonomous decay processes but can be regulated by signaling cascades originating from a small number of specialized cells within the nervous system. This supports a broader "neuro-hormonal" theory of aging, where the nervous system acts as a master controller, much like the mammalian hypothalamus is known to regulate systemic metabolism and aging. This study provides a specific molecular mechanism—an ion channel leading to a pH change that initiates a signaling cascade—that underpins this theory, elevating the importance of targeting the nervous system for systemic anti-aging interventions.

The functional benefits observed in the model organism were comprehensive:

- **Healthspan Extension:** Worms lacking the CLH-1 channel lived longer and, critically, maintained more youthful movement patterns into old age, indicating an extension of their functional healthspan.[1]
- **Systemic Stress Resistance:** The mutant worms exhibited lower levels of reactive

oxygen species (ROS) and demonstrated enhanced survival under conditions of oxidative stress, suggesting a globally improved resilience to cellular damage.[1]
- **Neuroprotection:** In a *C. elegans* model of Huntington's disease, the intervention resulted in fewer toxic protein aggregates. This indicates a protective effect against proteotoxicity, a hallmark of many age-related neurodegenerative diseases.[1]

Metabolic Control and the Microbiome: A New TOR-Inhibitor Class and the Agmatinase Axis

A study from Queen Mary University of London, published in *Communications Biology*, has identified that the next-generation TOR inhibitor, Rapalink-1, extends lifespan in yeast by acting on the TORC1 pathway. More importantly, the study uncovered a novel metabolic feedback loop involving agmatinases—enzymes that break down the metabolite agmatine—which regulates TOR activity and aging. As agmatine is produced by gut microbes, this finding forges a direct mechanistic link between the microbiome, metabolism, and a master regulatory pathway of aging.[2]

The mechanism of action centers on the Target of Rapamycin (TOR) pathway, a highly conserved regulator of growth and aging. Rapalink-1, a bi-steric inhibitor currently under investigation for anti-cancer properties, was shown to prolong the chronological lifespan of fission yeast.[3] The study's key insight came from identifying that TOR itself regulates the genes for agmatinases. These enzymes, in turn, control cellular levels of agmatine. When agmatinase function was lost, TOR activity increased, leading to faster cellular growth but also to premature aging. This establishes a feedback circuit where a microbially-influenced metabolite (agmatine) helps to fine-tune the activity of a central aging regulator (TOR), preventing its over-activation.[3]

The observed functional benefits in the yeast model system were clear:

- **Lifespan Extension:** Treatment with Rapalink-1 significantly extended the chronological lifespan of yeast, confirming its geroprotective properties.[3]
- **Metabolic Regulation:** The study demonstrates that the agmatinase pathway is essential for healthy aging in this model, directly linking metabolic control by a microbially-derived metabolite to longevity outcomes.[2]

Molecular Strategies for Neural and Retinal Regeneration

"Supercharged" Vitamin K Analogues for Neurogenesis in Mice

Scientists at Japan's Shibaura Institute of Technology have synthesized novel vitamin K analogues that are approximately three times more potent than natural vitamin K at inducing the differentiation of neural progenitor cells into new neurons.[5] The research, published in *ACS Chemical Neuroscience*, represents a potential shift toward regenerative therapies for neurodegenerative diseases.[7]

The most effective analogue, a hybrid of vitamin K and retinoic acid, was found to activate the metabotropic glutamate receptor 1 (mGluR1). Transcriptomic analysis and molecular docking simulations confirmed that this receptor activation mediates the downstream epigenetic and transcriptional changes that drive neurogenesis. This novel compound also demonstrated superior bioavailability in mouse models; it efficiently crossed the blood-brain barrier and achieved higher concentrations of its bioactive form (MK-4) in the brain compared to natural vitamin K.[5] The primary functional benefit is the enhanced capacity for neurogenesis, representing a direct mechanism for replacing lost neurons—a hallmark of diseases like Alzheimer's and Parkinson's. This offers a regenerative strategy rather than one that is merely protective or aims to slow decline.[5]

Bypassing the ELOVL2 "Aging Gene" to Restore Vision in Mice

Research from the University of California, Irvine, published in *Science Translational Medicine*, shows that supplementing aged mice with a specific polyunsaturated fatty acid (PUFA) can reverse age-related vision decline. The intervention works by bypassing the ELOVL2 enzyme, a well-established biomarker of aging whose function declines with age.[10]

The ELOVL2 gene is crucial for producing very-long-chain PUFAs (VLC-PUFAs) in the retina. This new study demonstrates that direct supplementation with a specific downstream PUFA can achieve vision restoration without needing to modulate the ELOVL2 enzyme itself. Notably, the beneficial effect was not seen with DHA supplementation alone, indicating a more specific lipid is required for this restorative effect.[10]

The functional benefits observed were twofold and significant:

- **Vision Restoration:** Aged mice receiving the PUFA injection showed improved visual

performance, a direct measure of functional recovery.[10]
- **Cellular Age Reversal:** The intervention was also shown to reverse molecular features of aging within retinal cells, demonstrating a deep restorative effect beyond simple functional improvement.[10]

Glycocalyx-Targeted Therapy Preserves Muscle Mass and Function in Aged Mice

A study in *Aging-US* from researchers at the University of New Mexico and the University of Utah provides compelling evidence that targeting the endothelial glycocalyx can prevent age-related muscle loss (sarcopenia) and preserve maximal exercise capacity in old mice.[12] The glycocalyx is a delicate gel-like lining of blood vessels that is known to degrade with age, and this study positions its integrity as a critical factor in maintaining musculoskeletal health.

The intervention involved a dietary supplement, Endocalyx™, which is rich in high-molecular-weight hyaluronan (HMW-HA), a key structural component of the glycocalyx. The therapy is believed to work by reinforcing this vascular lining, thereby improving microvascular function, enhancing blood flow and oxygen delivery to muscle tissue, and mitigating the chronic low-grade inflammation ("inflammaging") that drives muscle breakdown.[12] The importance of this pathway was first confirmed by showing that genetically deleting the enzyme responsible for HMW-HA production (Has2) in mice led directly to impaired exercise capacity and mitochondrial dysfunction.[14] This work reframes sarcopenia, at least in part, as a secondary consequence of vascular decline rather than a primary muscle pathology. By treating the "supply lines" (blood vessels), the researchers were able to preserve the "factory" (muscle), suggesting that interventions aimed at maintaining vascular health could be a highly effective upstream strategy to combat frailty.

The functional benefits in the aged mouse model were robust:

- **Preservation of Muscle Mass:** Old mice (29 months) on the Endocalyx™-supplemented diet for 10 weeks preserved muscle mass, whereas control mice experienced sarcopenia.[12]
- **Maintenance of Exercise Capacity:** The treated mice did not experience the age-related decline in running exercise capacity observed in the control group, maintaining higher time to exhaustion and work performed on a treadmill.[13]
- **Improved Mitochondrial Markers:** The supplement prevented the age-related decline in citrate synthase activity, a marker of mitochondrial content in skeletal muscle, linking vascular health directly to cellular energy production.[15]

Early-Stage Research vs. Clinical Trials: Assessing Translational Potential

A critical analysis of this week's findings reveals a wide spectrum of translational readiness, from foundational discoveries in simple organisms to preclinical interventions with a more direct, albeit complex, path to human application.

Foundational Discoveries (Yeast and *C. elegans*)

The discoveries in yeast and *C. elegans* are conceptually groundbreaking but are at the earliest stages of the research pipeline.

- **Glial pH Modulation:** The path to human translation is long. Mammalian glial cells are far more diverse and complex than the two AMsh glia in *C. elegans*. The feasibility of selectively and safely manipulating the intracellular pH of specific glial subtypes in the human brain without profound off-target effects is a formidable challenge.[16] This research opens an entirely new field of inquiry but is likely decades away from a direct therapeutic.
- **TOR/Agmatinase Axis:** The TOR pathway is highly conserved between yeast and humans, making this finding highly relevant.[18] While a direct therapy is distant, the immediate implication is for existing and future clinical trials of TOR inhibitors like rapamycin. These trials should now consider stratifying patients by microbiome composition or co-administering prebiotics to modulate the agmatine pathway, which could potentially enhance therapeutic efficacy and reduce variability in patient response.[2]

Preclinical Mammalian Research (Mice)

The interventions tested in mice are closer to clinical consideration, but each faces distinct developmental hurdles.

- **Vitamin K Analogues:** This research is promising due to the molecule's demonstrated

ability to cross the blood-brain barrier and its stable pharmacokinetic profile in mice.[5] The necessary next steps include long-term safety and toxicology studies in rodent and non-human primate models before a Phase 1 human trial could be designed. The primary indication would likely be a disease with high unmet need, such as early-stage Alzheimer's, not general cognitive enhancement in healthy individuals.[6]

- **PUFA for Vision:** The use of a naturally occurring fatty acid suggests a potentially favorable safety profile, and the "proof-of-concept" in mice is strong.[10] Translation will first require the precise identification of the specific PUFA used, followed by the development of a stable formulation for delivery to the human eye (e.g., intravitreal injection) and subsequent clinical trials for conditions like dry Age-Related Macular Degeneration (AMD).[10]
- **Glycocalyx Therapy:** The intervention uses a dietary supplement, which presents a faster but less rigorous path to market. While the mouse data on functional outcomes is compelling, initial human pilot studies on Endocalyx Pro have shown mixed results. A recent trial found no significant effect on overall glycocalyx thickness or flow-mediated dilation (FMD) in older adults, though some benefits were observed in specific subgroups (e.g., those not taking antihypertensive medication).[20] This highlights a significant translational gap between robust animal data and equivocal human data that must be resolved.

Table: Translational Readiness Scorecard

Intervention	Mechanism of Action	Model System	Key Functional Benefit	Key Translational Challenges	Estimated Readiness Level
Glial Cell pH Alkalinization	↑ pH in specific glia → systemic stress resistance	*C. elegans*	Extended lifespan & healthspan	Complexity of mammalian glia; targeted, safe delivery to the brain	**TRL 1 (Basic Research)**
Rapalink-1 / Agmatinase	TORC1 inhibition;	Yeast	Extended chronologic	Human validation	**TRL 2 (Translatio**

Modulation	modulation via microbial metabolite feedback loop		al lifespan	of agmatinase -TOR link; microbiome variability	**nal Research)**
"Supercharged" Vitamin K Analogue	mGluR1 activation → neurogenesis	Mice	Enhanced neuronal differentiation	Long-term safety/toxicology; human efficacy for neurodegeneration	**TRL 3 (Preclinical Development)**
Specific PUFA Supplementation	Bypasses ELOVL2 enzyme to restore retinal lipids	Mice	Reversal of age-related vision decline	Identification of specific PUFA; formulation for human delivery; clinical trials for AMD	**TRL 3 (Preclinical Development)**
Glycocalyx-Targeted Therapy (Endocalyx™)	HMW-HA supplementation to restore vascular lining	Mice / Humans	Preserved muscle mass & exercise capacity (mice)	Mixed results in human pilot studies; supplement vs. drug pathway	**TRL 4/5 (Clinical Validation ongoing)**

Technological Tools: New Platforms for Aiding Longevity Research

Modeling Human Resilience: The Centenarian Induced Pluripotent Stem Cell (iPSC) Platform

A significant technological advance was reported in a bioRxiv preprint from researchers at Boston University and collaborating institutions: the establishment of a first-of-its-kind iPSC-based platform derived from centenarians. This platform is designed to model and experimentally interrogate the biological mechanisms of resilience and exceptional longevity.[22]

This platform represents a paradigm shift from the historically observational and correlational studies of centenarians to mechanistic, experimental science. It provides a critical bridge between human genetics and functional genomics. For decades, Genome-Wide Association Studies (GWAS) have identified genetic variants statistically associated with longevity, but linking these variants to a causal, cellular effect has been a major bottleneck. This iPSC platform provides the missing link. Researchers can now identify a longevity-associated gene variant from a GWAS, find a centenarian donor with that variant, create iPSCs, differentiate them into relevant cell types (e.g., neurons, cardiomyocytes), and directly study the *function* that variant confers. This closes the loop between statistical association and causal cell biology, dramatically accelerating the validation of genetic targets for therapeutic intervention.

The technological significance is multifaceted, allowing researchers to:

- Generate a virtually unlimited supply of patient-specific cells (e.g., neurons, immune cells) that carry the unique genetic and epigenetic signatures of exceptional longevity.[22]
- Conduct controlled experiments *in vitro* to test how these "resilient" cells respond to various stressors (e.g., oxidative, proteostatic, metabolic) compared to cells from average-aging individuals.[22]
- Perform high-throughput screening of chemical compounds to identify drugs that can induce or mimic the "resilience signature" observed in centenarian-derived cells.[22]

Initial findings reported in the preprint are already promising. Neurons derived from centenarian iPSCs exhibit distinct transcriptional and functional signatures, including enhanced synaptic integrity pathways, more stable calcium dynamics, and a more robust and efficient response to cellular stress when compared to non-centenarian controls.[22]

Ethical and Practical Considerations

The rapid pace of discovery in longevity science necessitates a concurrent and rigorous examination of the ethical and practical challenges associated with translating these findings.

Safety and Off-Target Effects of Novel Molecules

The development of novel chemical entities such as the "supercharged" vitamin K analogues and Rapalink-1 carries inherent risks. While designed for specific targets (mGluR1 and TORC1, respectively), the potential for off-target effects, long-term toxicity, and unforeseen consequences of modulating fundamental cellular pathways is significant.[6] The ethical imperative is to ensure that the risk of any proposed intervention does not outweigh the risk of the age-related condition being treated, which requires extensive preclinical toxicology and long-term safety studies before human trials can be justified.

The Regulatory Gray Zone of "Functional Foods" and Supplements

The glycocalyx therapy, Endocalyx™, is marketed as a dietary supplement, a classification that allows it to bypass the rigorous efficacy and safety trials required for FDA drug approval.[26] This creates a significant practical and ethical concern. Robust preclinical data, such as that from the mouse study showing preserved muscle mass, can be used in marketing materials, even if human clinical data remains equivocal or shows limited effect.[20] This creates a scenario where consumers may be misled about proven efficacy, purchasing products based on the promise of animal studies that has not yet been validated in humans.

Ethical Landscape of the Centenarian iPSC Platform

The creation of an iPSC bank from centenarians, while technologically powerful, navigates a complex ethical landscape.

- **Informed Consent:** Obtaining truly informed consent from very elderly individuals (100+) for the creation of immortal cell lines with vast and unforeseeable future research applications is ethically complex. The process must be exceptionally rigorous to ensure donors fully comprehend the implications—including the creation of a permanent

biological resource from their cells—without feeling pressured or unduly influenced.[27]

- **Genetic Privacy and Commercialization:** These cell lines contain the "genetic secrets" of exceptional longevity. This raises profound ethical questions regarding data privacy, ownership of the cell lines, and the potential for commercialization of discoveries derived from them. Policies must be established to address how original donors or their families might share in any potential financial benefits and how their genetic data will be protected.[27]
- **The "Slippery Slope" Argument:** Research into the genetic basis of exceptional health and longevity inevitably raises societal concerns about its potential use for non-therapeutic enhancement. There is a risk that such technologies could exacerbate social inequities, creating a world where only the wealthy can afford to access biological advantages, a concern that requires proactive public discourse and policy development.[30]

Long-Term Consequences of Microbiome Manipulation

The agmatinase/TOR research highlights that targeted microbial or metabolic interventions could be a powerful longevity strategy.[2] However, the gut microbiome is a complex ecosystem. The long-term consequences of deliberately and permanently altering this ecosystem are largely unknown. Interventions designed to promote longevity could have unintended negative effects on host immunity, metabolism, or susceptibility to other diseases in the long run.[31] The ethical principle of *primum non nocere* (first, do no harm) requires extreme caution and a deep understanding of ecological dynamics before such interventions are widely deployed.

Future Directions and Strategic Outlook

This week's research reinforces a multi-pillar approach to extending healthspan. Progress is evident in: 1) understanding fundamental, centrally-controlled aging pathways (glia, TOR); 2) developing targeted, regenerative molecules for high-value functions (vision, cognition); 3) creating powerful new platforms to study human-specific resilience (centenarian iPSCs); and 4) validating the mechanistic importance of lifestyle factors, as seen in recent studies linking strong social connections to slower epigenetic aging.[33]

The projected next steps for this week's key findings follow a logical translational path:

- **Glial pH:** The immediate priority is to validate these findings in mammalian systems. This

will likely involve using mouse models with astrocyte-specific gene knockouts or employing brain organoids to study human glial cell pH dynamics and their downstream signaling effects.[36]

- **Agmatinase/TOR Axis:** Research must now move from yeast to mammals. This will involve creating mouse models with modified agmatinase activity to study their response to TOR inhibitors like rapamycin, while also analyzing their microbiome and metabolome to confirm the conservation of this feedback loop.[37]
- **Vitamin K Analogues:** The clear path forward is comprehensive preclinical safety and toxicology studies in at least two animal models. Success there would enable the design of a Phase 1 human trial focused on safety and pharmacokinetics in a patient population with a clear unmet need, such as those with mild cognitive impairment.[38]
- **Centenarian iPSC Platform:** The platform is now ready for widespread deployment. The next steps are to expand the cell bank to include more donors, differentiate the cells into a wider variety of tissues relevant to aging (e.g., cardiomyocytes, immune cells), and begin high-throughput drug screening to identify molecules that can pharmacologically induce the observed "resilience signature".[36]

Concluding Expert Analysis: Most Impactful Discovery of the Week

While the molecular interventions for regeneration are exciting and tangible, the most strategically significant development this week is the **establishment of the centenarian induced pluripotent stem cell (iPSC) platform**.

This is not just a single discovery but an *enabling technology* that will accelerate the entire field of geroscience. It provides, for the first time, a scalable, experimentally tractable *human* model of healthy aging and resilience. It allows researchers to move beyond the limitations of model organisms and directly test hypotheses about human longevity. Its potential to validate genetic targets, screen for novel geroprotective drugs, and uncover fundamental protective mechanisms makes it the foundational advance from which dozens of future discoveries will likely originate. It represents the physical embodiment of the crucial strategic shift in the field: from studying disease to studying the biology of exceptional health.

Works cited

1. Worms and Aging: How Non-Neural Cells in the Central Nervous ..., accessed October 15, 2025, https://news.med.miami.edu/worms-and-aging-how-non-neural-cells-in-the-central-nervous-system-could-spur-longevity/
2. Whole new class of anti-ageing drug found to work at cell level, accessed October 15, 2025,

https://ca.news.yahoo.com/whole-class-anti-ageing-drug-045559656.html
3. New drug and enzyme class found to have anti-ageing properties ..., accessed October 15, 2025, https://www.eurekalert.org/news-releases/1099727
4. (PDF) Rapalink-1 reveals TOR-dependent genes and an ..., accessed October 15, 2025, https://www.researchgate.net/publication/395971293_Rapalink-1_reveals_TOR-dependent_genes_and_an_agmatinergic_axis-based_metabolic_feedback_regulating_TOR_activity_and_lifespan_in_fission_yeast
5. Supercharged vitamin k could help the brain heal itself - ScienceDaily, accessed October 15, 2025, https://www.sciencedaily.com/releases/2025/10/251014014312.htm
6. Novel vitamin K analogs show promise for reversing neurodegenerative diseases, accessed October 15, 2025, https://www.news-medical.net/news/20250913/Novel-vitamin-K-analogs-show-promise-for-reversing-neurodegenerative-diseases.aspx
7. Mind & Brain News - ScienceDaily, accessed October 15, 2025, https://www.sciencedaily.com/news/mind_brain/
8. RSS Feed - Science Daily - TLCI - The Latino Cancer Institute, accessed October 15, 2025, https://latinocancerinstitute.org/rss-feed-science-daily/
9. Vitamin K analogues may help transform the treatment of neurodegenerative diseases, accessed October 15, 2025, https://www.eurekalert.org/news-releases/1098044
10. A simple fatty acid could restore failing vision | ScienceDaily, accessed October 15, 2025, https://www.sciencedaily.com/releases/2025/10/251014014307.htm
11. Health & Medicine News - ScienceDaily, accessed October 15, 2025, https://www.sciencedaily.com/news/health_medicine/
12. Supplement Supporting Blood Vessel Glycocalyx Shows Promise in Reducing Frailty Among Older Adults - Bioengineer.org, accessed October 15, 2025, https://bioengineer.org/supplement-supporting-blood-vessel-glycocalyx-shows-promise-in-reducing-frailty-among-older-adults/
13. Glycocalyx-targeted therapy prevents age-related muscle loss and declines in maximal exercise capacity, accessed October 15, 2025, https://www.aging-us.com/article/206313
14. Glycocalyx-targeted therapy prevents age-related ... - Aging-US, accessed October 15, 2025, https://www.aging-us.com/article/206313/pdf
15. Glycocalyx-targeted therapy prevents age-related muscle loss and declines in maximal exercise capacity - PubMed, accessed October 15, 2025, https://pubmed.ncbi.nlm.nih.gov/40892009/
16. Quantitative profiling pH heterogeneity of acidic endolysosomal compartments using fluorescence lifetime imaging microscopy - Molecular Biology of the Cell (MBoC), accessed October 15, 2025, https://www.molbiolcell.org/doi/10.1091/mbc.E23-06-0220
17. Ensheathing glia promote increased lifespan and healthy brain aging - PMC, accessed October 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10186613/
18. Extending Healthy Life Span--From Yeast to Humans - ResearchGate, accessed

October 15, 2025, https://www.researchgate.net/publication/43160027_Extending_Healthy_Life_Span--From_Yeast_to_Humans
19. Insights into the Conserved Regulatory Mechanisms of Human and Yeast Aging - PMC, accessed October 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7355435/
20. Effect of glycocalyx-targeted therapy on vascular function in older adults: a randomized controlled trial - PMC, accessed October 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12461737/
21. Effect of glycocalyx-targeted therapy on vascular function in older adults: a randomized controlled trial - American Journal of Physiology, accessed October 15, 2025, https://journals.physiology.org/doi/abs/10.1152/japplphysiol.00150.2024
22. IPSC-based modeling of resiliency in centenarians reveals longevity-specific signatures - bioRxiv, accessed October 15, 2025, https://www.biorxiv.org/content/10.1101/2025.10.10.681757v1.full.pdf
23. IPSC-based modeling of resiliency in centenarians reveals longevity ..., accessed October 15, 2025, https://www.biorxiv.org/content/10.1101/2025.10.10.681757v1
24. Currently Funded Studies | New England Centenarian Study | Page 1000, accessed October 15, 2025, https://www.bumc.bu.edu/centenarian/studies/1000/
25. Rapalink-1 - Wikipedia, accessed October 15, 2025, https://en.wikipedia.org/wiki/Rapalink-1
26. Is Endocalyx (Endocalyx, a hemostatic agent) accepted as legitimate? - Dr.Oracle, accessed October 15, 2025, https://www.droracle.ai/articles/126023/is-endocalyx-accepted-as-legitamate
27. Ethics and Induced Pluripotent Stem Cells | Embryo Project Encyclopedia, accessed October 15, 2025, https://embryo.asu.edu/pages/ethics-and-induced-pluripotent-stem-cells
28. Content and Method of Information for Participants in Clinical Studies With Induced Pluripotent Stem Cells (iPSCs) - Frontiers, accessed October 15, 2025, https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.627816/full
29. What are the ethical considerations surrounding stem cell anti-aging treatments in 2024?, accessed October 15, 2025, https://www.skinloft.com/what-are-the-ethical-considerations-surrounding-stem-cell-anti-aging-treatments-in-2024/
30. What are the Ethical Concerns of Genome Editing?, accessed October 15, 2025, https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns
31. Microbiome-based therapeutics towards healthier aging and longevity - ResearchGate, accessed October 15, 2025, https://www.researchgate.net/publication/393254848_Microbiome-based_therapeutics_towards_healthier_aging_and_longevity
32. The Human Microbiome and Public Health: Social and Ethical Considerations - PMC, accessed October 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4815753/

33. Strong social connections could boost healthy aging, experts say, accessed October 15, 2025, https://hsph.harvard.edu/news/strong-social-connections-could-boost-healthy-aging-experts-say/
34. Strong Social Ties May Slow Biological Aging - Everyday Health, accessed October 15, 2025, https://www.everydayhealth.com/healthy-living/strong-social-ties-may-slow-biological-aging/
35. Strong friendships may literally slow aging at the cellular level - ScienceDaily, accessed October 15, 2025, https://www.sciencedaily.com/releases/2025/10/251004092917.htm
36. accessed December 31, 1969, https://www.science.org/doi/10.1126/sciadv.adp0369
37. accessed December 31, 1969, https://www.nature.com/articles/s42003-025-08731-3
38. A New Class of Vitamin K Analogues Containing the Side Chain of ..., accessed October 15, 2025, https://pubs.acs.org/doi/10.1021/acschemneuro.5c00111